Aura Energy* (AURA LN) – Swedish compensation claim to be handled by Chancellor of Justice in Sweden | Cora Gold* (CORA LN) – Sanankoro scoping study delivers attractive economics | Scotgold Resources* (SGZ LN) – Exploration update | Shanta Gold (SHG LN) – Robust Q4 results conclude strong FY19 year | Phoenix Copper* (PXC LN) – Ryan McDermott moves into CEO role as company heads towards production from Red Star project.

AURA CORA SGZ SHG PXC

• 16 Jan 20
• -
• 

Aura Energy* (AURA LN) – Swedish compensation claim to be handled by Chancellor of Justice in Sweden | Cora Gold* (CORA LN) – Sanankoro scoping study delivers attractive economics | Scotgold Resources* (SGZ LN) – Exploration update | Shanta Gold (SHG LN) – Robust Q4 results conclude strong FY19 year | Phoenix Copper* (PXC LN) – Ryan McDermott moves into CEO role as company heads towards production from Red Star project.

AURA CORA SGZ SHG PXC

• 16 Jan 20
• -
• 

Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently enables fast access to 11 US glioblastoma centers. GDC-0084 could be dosed from Q2/Q3 CY20. Data from the 20-patient stage of the GDC-0084 Phase II should be available during 2020. Our indicative value remains at $93m.

Novogen

• 13 Jan 20
• -
• 

Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently enables fast access to 11 US glioblastoma centers. GDC-0084 could be dosed from Q2/Q3 CY20. Data from the 20-patient stage of the GDC-0084 Phase II should be available during 2020. Our indicative value remains at $93m.

Novogen

• 13 Jan 20
• -
• 

Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently enables fast access to 11 US glioblastoma centres. GDC-0084 could be dosed from Q2/Q3 CY20. Data from the 20-patient stage of the GDC-0084 Phase II should be available during 2020. Our indicative value remains at A$137m.

Novogen

• 13 Jan 20
• -
• 

Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently enables fast access to 11 US glioblastoma centres. GDC-0084 could be dosed from Q2/Q3 CY20. Data from the 20-patient stage of the GDC-0084 Phase II should be available during 2020. Our indicative value remains at A$137m.

Novogen

• 13 Jan 20
• -
• 

Pacific Edge continues to make progress commercialising its Cxbladder suite of bladder cancer diagnostics products, with three of the four Cxbladder tests available in the US market. Cxbladder was recently included in the National Comprehensive Cancer Network (NCCN) guidelines for bladder cancer. The company also submitted an updated evidence dossier to its Medicare Administrative Contractor (MAC), which may decide in Q2 CY20 whether Cxbladder will be included in a Local Coverage Determination (LCD) by the US Centers for Medicare and Medicaid Services (CMS). This will be a key milestone for the company as approximately 47% of US lab throughput for the company is for patients covered by CMS.

Pacific Edge

• 06 Jan 20
• -
• 

Pacific Edge continues to make progress commercialising its Cxbladder suite of bladder cancer diagnostics products, with three of the four Cxbladder tests available in the US market. Cxbladder was recently included in the National Comprehensive Cancer Network (NCCN) guidelines for bladder cancer. The company also submitted an updated evidence dossier to its Medicare Administrative Contractor (MAC), which may decide in Q2 CY20 whether Cxbladder will be included in a Local Coverage Determination (LCD) by the US Centers for Medicare and Medicaid Services (CMS). This will be a key milestone for the company as approximately 47% of US lab throughput for the company is for patients covered by CMS.

Pacific Edge

• 06 Jan 20
• -
• 

Mesoblast is approaching some very key catalysts. The company expects to complete its filing of Remestemcel-L in pediatric acute graft versus host disease (aGvHD) in January, which if approved, will launch in 2020. For Revascor for advanced heart failure, the required accrual of primary endpoint events in its Phase III occurred in December, with data expected by mid-2020. Additionally, the last patient visit for the 24-month follow-up in the Phase III for MPC-06-ID in low back pain is expected to occur in H120 with data likely later in the year.

Mesoblast

• 03 Jan 20
• -
• 

Mesoblast is approaching some very key catalysts. The company expects to complete its filing of Remestemcel-L in pediatric acute graft versus host disease (aGvHD) in January, which if approved, will launch in 2020. For Revascor for advanced heart failure, the required accrual of primary endpoint events in its Phase III occurred in December, with data expected by mid-2020. Additionally, the last patient visit for the 24-month follow-up in the Phase III for MPC-06-ID in low back pain is expected to occur in H120 with data likely later in the year.

Mesoblast

• 03 Jan 20
• -
• 

SDI VLTY AQX VLG TWD PHC TUNE CIR WSG BIDS

• 19 Dec 19
• -
• 

SDI VLTY AQX VLG TWD PHC TUNE CIR WSG BIDS

• 19 Dec 19
• -
• 

Ariana Resources (AAU LN) – Kiziltepe resource drilling | Condor Gold (CNR LN) – Sale of the Poterillos concession | Eurasia Mining (EUA LN) – Monchetundra Flanks license update | KEFI Minerals* (KEFI LN) – Tulu Kapi funding update, award of 1,200km2 exploration license and a £1.9m equity placing | Renascor Resources Ltd (RNU AU) BUY - Valuation A$0.09/s - Siviour graphite DFS demonstrates value - Initiation note | Talga Resources* (TLG AU) – Valuation: A$1.80 – Talcoat Commercial Graphene coating trial on cargo ship

AAU CNR EUA KEFI TLG

• 17 Dec 19
• -
• 

Ariana Resources (AAU LN) – Kiziltepe resource drilling | Condor Gold (CNR LN) – Sale of the Poterillos concession | Eurasia Mining (EUA LN) – Monchetundra Flanks license update | KEFI Minerals* (KEFI LN) – Tulu Kapi funding update, award of 1,200km2 exploration license and a £1.9m equity placing | Renascor Resources Ltd (RNU AU) BUY - Valuation A$0.09/s - Siviour graphite DFS demonstrates value - Initiation note | Talga Resources* (TLG AU) – Valuation: A$1.80 – Talcoat Commercial Graphene coating trial on cargo ship

AAU CNR EUA KEFI TLG

• 17 Dec 19
• -
• 

Pure Gold Mining (PUR LN) 42pence & Mkt Cap £151.8m – Drilling results from Madsden Red Lake | Sunrise Resources Plc (SRES LN) 0.13 pence, Mkt Cap £4.0m – CS Project secures water rights | Scotgold Resources* (SGZ LN) 63p, Mkt Cap £31m – Plant commissioning delayed to May/20 | Shanta Gold (SHG LN) 9.3p, Mkt Cap £73m – Exploration drilling returns high grade intersections at New Luika | Vast Resources* (VAST LN) 0.29p, Mkt Cap £30m – Baita Plai cold commissioning | Sirius (SXX LN) - Ding dong Sirius share are high – A Christmas Carol

PUR SRES SGZ SHG VAST SXX

• 16 Dec 19
• -
• 

Pure Gold Mining (PUR LN) 42pence & Mkt Cap £151.8m – Drilling results from Madsden Red Lake | Sunrise Resources Plc (SRES LN) 0.13 pence, Mkt Cap £4.0m – CS Project secures water rights | Scotgold Resources* (SGZ LN) 63p, Mkt Cap £31m – Plant commissioning delayed to May/20 | Shanta Gold (SHG LN) 9.3p, Mkt Cap £73m – Exploration drilling returns high grade intersections at New Luika | Vast Resources* (VAST LN) 0.29p, Mkt Cap £30m – Baita Plai cold commissioning | Sirius (SXX LN) - Ding dong Sirius share are high – A Christmas Carol

PUR SRES SGZ SHG VAST SXX

• 16 Dec 19
• -
• 

Cora Gold* (CORA LN) 5.8p, Mkt Cap £7.5m – Exploration update | Edenville Energy* (EDL LN) 0.04p, Mkt Cap £2.2m – New coal supply contracts signed for up to 9ktpm | Magnis Energy Technologies (MNS AU) A$0.096, Mkt cap A$60m – Magnis executes binding EPC contract with China MCC | Renascor Resources* (RNU AU) A$0.011, Mkt Cap A$13m – Approval for production for large-scale marketing samples | Rio Tinto (RIO LN) 4307.5, Mkt cap £73.0bn – Mongolian Parliament provides greater clarity on Oyu Tolgoi | Savannah Resources* (SAV LN) 2.3p, Mkt Cap £29.8m – Second mining licence issued at Mutamba | Teranga Gold (TGZ CN) C$6.19, Mkt Cap C$666m – Acquiring the Massawa gold project in Senegal

CORA EDL RIO SAV TGZ

• 11 Dec 19
• -
• 

Cora Gold* (CORA LN) 5.8p, Mkt Cap £7.5m – Exploration update | Edenville Energy* (EDL LN) 0.04p, Mkt Cap £2.2m – New coal supply contracts signed for up to 9ktpm | Magnis Energy Technologies (MNS AU) A$0.096, Mkt cap A$60m – Magnis executes binding EPC contract with China MCC | Renascor Resources* (RNU AU) A$0.011, Mkt Cap A$13m – Approval for production for large-scale marketing samples | Rio Tinto (RIO LN) 4307.5, Mkt cap £73.0bn – Mongolian Parliament provides greater clarity on Oyu Tolgoi | Savannah Resources* (SAV LN) 2.3p, Mkt Cap £29.8m – Second mining licence issued at Mutamba | Teranga Gold (TGZ CN) C$6.19, Mkt Cap C$666m – Acquiring the Massawa gold project in Senegal

CORA EDL RIO SAV TGZ

• 11 Dec 19
• -
• 

Ariana Resources (AAU LN) – Due diligence at Salinbas | Bougainville – Vote on independence may enable restoration of production at historic Bougainville copper mine | Glencore (GLEN LN) – Investors line up to sue Glencore following share price fall on SFO investigation | Landore Resources (LND LN) – Soil sampling identifies additional drill targets at BAM gold project | Savannah Resources* (SAV LN) – Mining licence issued at Mutamba

AAU BOC GLEN LND SAV

• 09 Dec 19
• -
• 

Ariana Resources (AAU LN) – Due diligence at Salinbas | Bougainville – Vote on independence may enable restoration of production at historic Bougainville copper mine | Glencore (GLEN LN) – Investors line up to sue Glencore following share price fall on SFO investigation | Landore Resources (LND LN) – Soil sampling identifies additional drill targets at BAM gold project | Savannah Resources* (SAV LN) – Mining licence issued at Mutamba

AAU BOC GLEN LND SAV

• 09 Dec 19
• -
•